Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Shares Outstanding (Diluted Average) (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 11.02% to $6.8 million in Q4 2025 year-over-year; TTM through Oct 2025 was $6.8 million, a 11.02% decrease, with the full-year FY2025 number at $7.3 million, down 23.5% from a year prior.
  • Shares Outstanding (Diluted Average) was $6.8 million for Q4 2025 at PharmaCyte Biotech, roughly flat from $6.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $21.7 million in Q1 2022 to a low of $1.4 million in Q2 2021.
  • A 5-year average of $11.8 million and a median of $9.6 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 1208.94% in 2022, then tumbled 57.08% in 2024.
  • PharmaCyte Biotech's Shares Outstanding (Diluted Average) stood at $17.4 million in 2021, then increased by 18.59% to $20.6 million in 2022, then tumbled by 48.1% to $10.7 million in 2023, then fell by 28.52% to $7.6 million in 2024, then decreased by 11.02% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Shares Outstanding (Diluted Average) are $6.8 million (Q4 2025), $6.8 million (Q3 2025), and $7.3 million (Q2 2025).